https://pepsreview.com/articles/state-attorneys-general-flag-china-drug-supply-chain-exploitation PepsReview en 2026-09-18 China drug supply chain, FDA approved drugs, National Security Council, state attorneys general, counterfeit weight-loss drugs, pharmaceutical API sourcing, peptide testing https://pepsreview.com/articles/oral-obesity-drugs-south-korea-approval-filings PepsReview en 2026-09-17 oral GLP-1, South Korea obesity drug approval, orforglipron, oral semaglutide, MFDS, GLP-1 market Asia, weight loss pill, Novo Nordisk Eli Lilly https://pepsreview.com/articles/novo-returns-once-monthly-glp-1-rights-to-ascendis-pipeline-reset PepsReview en 2026-09-17 Novo Nordisk, Ascendis Pharma, GLP-1 pipeline, once-monthly semaglutide, obesity drug development, pharmaceutical licensing, TransCon technology https://pepsreview.com/articles/glp-1-makers-paid-270000-doctors-federal-disclosures-show PepsReview en 2026-09-17 GLP-1 payments, Open Payments, Eli Lilly, Novo Nordisk, physician disclosure, weight-loss drug marketing, prescribing conflicts, pharmaceutical transparency https://pepsreview.com/articles/glp-1-brain-disorder-thiamine-deficiency-study PepsReview en 2026-09-17 GLP-1 brain disorder, thiamine deficiency, Wernicke encephalopathy, semaglutide safety, weight-loss drug risks, vitamin B1, adverse events, neurologic complications